94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1580550
Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis
Provisionally accepted- 1Department of Hematology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- 3Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, Yunnan Province, China
- 4Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, The First People's Hospital of Yunnan Province, Yunnan, China
- 5Yunnan Provincial Key Laboratory of Innovative application of characteristic Chinese Materia Medica, The First People's Hospital of Yunnan Province, Yunnan, China
- 6Department of Pathology, The First People’s Hospital of Yunnan Province, Kunming, Yunnan Province, China
- 7Department of Pathology, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The relationship between atopic dermatitis (AD) and lymphoma risk remains debate. This study systematically evaluates lymphoma risk in AD patients compared to non-AD individuals.A systematic search of PubMed, Embase, and the Cochrane Library (up to August 11, 2024) identified observational studies reporting lymphoma risk estimates for AD patients. Pooled odds ratios (OR) or relative risks (RR) with 95% CIs were calculated using a random-effects model (PROSPERO ID: CRD42024577019).Results: Of 2,366 articles were screened, 13 studies met the inclusion criteria. AD was significantly associated with elevated lymphoma risk (OR = 2.56, 95% CI: 1.75-3.74, P < 0.001; RR = 1.23, 95% CI:1.15-1.31, P < 0.001). The risk increased with AD severity, with severe cases showing the highest effect size (RR = 2.63; 95% CI: 1.94-3.58, P < 0.001; OR = 2.60; 95% CI: 1.71-3.96, P < 0.001). Subgroup analyses revealed high risks for Hodgkin lymphoma (HL) (RR = 1.54, 95% CI: 1.35-1.75, P < 0.001) and non-Hodgkin lymphoma (RR = 1.15, 95% CI: 1.04-1.28, P = 0.006). Notably, T-cell lymphoma (TCL) showed the highest risk (OR = 4.25; 95% CI: 1.94-9.33, P < 0.001). whereas no significant association was observed for B-cell lymphoma (OR = 1.07; 95% CI: 0.95-1.20, P = 0.271).AD is significantly association with increased lymphoma risk, particularly HL, NHL and TCL. AD severity may amplify this risk. Future research is warranted to explore underlying mechanisms and address limitations in the current evidence.Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024577019.
Keywords: atopic dermatitis, Lymphoma, T-cell lymphoma, Systematic review, Meta-analysis
Received: 20 Feb 2025; Accepted: 21 Mar 2025.
Copyright: © 2025 TIAN, Li, Chen, Yuan, Peng, Su and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liang Su, Department of Hematology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Jie Wu, Department of Hematology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.